Drospirenone/Ethinylestradiol: A Review on Efficacy and Noncontraceptive Benefits

Citations Over TimeTop 17% of 2010 papers

Abstract

Considerable advances have been made in the field of combined oral contraceptives since their introduction 50 years ago. This ongoing evolution has been focused on reducing the estrogen dose and synthesizing new progestogens. A recently launched combination of ethinylestradiol 20 µg and drospirenone 3 mg demonstrates the advantages of a lower estrogen dose with the antimineralocorticoid activity of drospirenone that is responsible for the drug's significant antiandrogenic and antimineralocorticoid effects, reflected clinically in lower rates of adverse events including less fluid retention. In addition to the drug's contraceptive efficacy, its effects on the skin and other classic noncontraceptive benefits, the ethinylestradiol 20 µg and drospirenone 3 mg combination has demonstrated highly satisfactory results in women with premenstrual dysphoric syndrome.

Related Papers

• → Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone(2004)112 cited
• → A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers(2000)59 cited
• → A Comparison of the Cycle Control, Safety, and Efficacy Profile of a 21-Day Regimen of Ethinylestradiol 20??g and Drospirenone 3mg with a 21-Day Regimen of Ethinylestradiol 20??g and Desogestrel??150??g(2006)26 cited
• → Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers(2000)62 cited
• → Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives(2008)9 cited